共 111 条
[1]
Desjeux P(1996)Leishmaniasis. Public health aspects and control Clin Dermatol 14 417-423
[2]
Zijlstra EE(2003)Post-kala-azar dermal leishmaniasis Lancet Infect Dis 3 87-98
[3]
Musa AM(2010)Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial PLoS Negl Trop Dis 4 e709-194
[4]
Khalil EA(2010)Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study PLoS Negl Trop Dis 4 e855-364
[5]
el-Hassan IM(2010)Combination therapy for visceral leishmaniasis Lancet Infect Dis 10 184-598
[6]
el-Hassan AM(2006)A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection Clin Infect Dis 43 357-1746
[7]
Hailu A(2007)Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis J Infect Dis 196 591-486
[8]
Musa A(2002)Oral miltefosine for Indian visceral leishmaniasis N Engl J Med 347 1739-917
[9]
Wasunna M(2011)Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial Lancet 377 477-2860
[10]
Balasegaram M(2002)Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections Malar J 1 13-62